Clearside Biomedical, Inc. (CLSD): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLSD POWR Grades
- CLSD scores best on the Value dimension, with a Value rank ahead of 82.18% of US stocks.
- The strongest trend for CLSD is in Momentum, which has been heading up over the past 179 days.
- CLSD ranks lowest in Growth; there it ranks in the 7th percentile.
CLSD Stock Summary
- With a year-over-year growth in debt of 4,166.76%, CLEARSIDE BIOMEDICAL INC's debt growth rate surpasses 99.31% of about US stocks.
- Revenue growth over the past 12 months for CLEARSIDE BIOMEDICAL INC comes in at 584.38%, a number that bests 98.21% of the US stocks we're tracking.
- CLEARSIDE BIOMEDICAL INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -46.28%, greater than the shareholder yield of only 11.58% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to CLEARSIDE BIOMEDICAL INC, a group of peers worth examining would be SLDP, AKTS, MRKR, ADCT, and YMAB.
- Visit CLSD's SEC page to see the company's official filings. To visit the company's web site, go to www.clearsidebio.com.
CLSD Valuation Summary
- In comparison to the median Healthcare stock, CLSD's price/earnings ratio is 166.81% lower, now standing at -15.5.
- Over the past 79 months, CLSD's price/earnings ratio has gone down 8.2.
Below are key valuation metrics over time for CLSD.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLSD | 2022-11-25 | 2.7 | 3.8 | -15.5 | -10.9 |
| CLSD | 2022-11-23 | 2.7 | 3.8 | -15.5 | -10.9 |
| CLSD | 2022-11-22 | 2.6 | 3.7 | -15.0 | -10.4 |
| CLSD | 2022-11-21 | 2.6 | 3.7 | -15.0 | -10.4 |
| CLSD | 2022-11-18 | 2.7 | 3.9 | -15.9 | -11.3 |
| CLSD | 2022-11-17 | 3.0 | 4.4 | -17.8 | -13.1 |
CLSD Growth Metrics
- The 5 year price growth rate now stands at -74.93%.
- The 3 year net cashflow from operations growth rate now stands at 98.29%.
- Its 4 year net cashflow from operations growth rate is now at 24.18%.
The table below shows CLSD's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 26.684 | -2.704 | -4.575 |
| 2022-06-30 | 29.492 | 0.204 | -1.635 |
| 2022-03-31 | 29.888 | -1.303 | 0.083 |
| 2021-12-31 | 29.575 | -10.733 | 0.376 |
| 2021-09-30 | 3.899 | -20.223 | -25.445 |
| 2021-06-30 | 4.257 | -19.606 | -22.991 |
CLSD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CLSD has a Quality Grade of C, ranking ahead of 52.15% of graded US stocks.
- CLSD's asset turnover comes in at 0.183 -- ranking 206th of 681 Pharmaceutical Products stocks.
- GLYC, MDVL, and XENE are the stocks whose asset turnover ratios are most correlated with CLSD.
The table below shows CLSD's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.183 | 1 | 3.825 |
| 2021-03-31 | 0.186 | 1 | 3.961 |
| 2020-12-31 | 0.397 | 1 | 3.928 |
| 2020-09-30 | 0.452 | 1 | 4.357 |
| 2020-06-30 | 0.274 | 1 | 13.716 |
| 2020-03-31 | 0.232 | 1 | -11.517 |
CLSD Price Target
For more insight on analysts targets of CLSD, see our CLSD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $11.60 | Average Broker Recommendation | 1.58 (Moderate Buy) |
CLSD Stock Price Chart Interactive Chart >
CLSD Price/Volume Stats
| Current price | $1.20 | 52-week high | $3.38 |
| Prev. close | $1.18 | 52-week low | $1.00 |
| Day low | $1.16 | Volume | 63,460 |
| Day high | $1.20 | Avg. volume | 424,686 |
| 50-day MA | $1.22 | Dividend yield | N/A |
| 200-day MA | $1.53 | Market Cap | 72.23M |
Clearside Biomedical, Inc. (CLSD) Company Bio
Clearside Biomedical, a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. The company was founded in 2011 and is based in Alpharetta, Georgia
Latest CLSD News From Around the Web
Below are the latest news stories about CLEARSIDE BIOMEDICAL INC that investors may wish to consider to help them evaluate CLSD as an investment opportunity.
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following conferences in November and December 2022: BTIG Ophthalmology DayFireside ChatTuesday, November 29, 2022 at 10:30 a.m. ET Piper Sandler 34th Annual Healthcare ConferenceCorporate PresentationThursday, Decemb |
Clearside Biomedical Third Quarter 2022 Earnings: Beats ExpectationsClearside Biomedical ( NASDAQ:CLSD ) Third Quarter 2022 Results Key Financial Results Revenue: US$266.0k (down 91% from... |
Clearside Biomedical (CLSD) Gets a Buy from H.C. WainwrightH.C. Wainwright analyst Yi Chen reiterated a Buy rating on Clearside Biomedical (CLSD - Research Report) today and set a price target of $6.00. The company's shares closed yesterday at $1.28.According to TipRanks, Chen is an analyst with an average return of -26.0% and a 25.82% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals.Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $6.50, which is a 407.81% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target. |
Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP) and Clearside Biomedical (CLSD)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Armata Pharmaceuticals (ARMP – Research Report) and Clearside Biomedical (CLSD – Research Report) with bullish sentiments. Armata Pharmaceuticals (ARMP) Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Armata Pharmaceuticals today and set a price target of $9.00. The company's shares closed last Wednesday at $3.28, close to its 52-week low of $2.82. According to TipRanks.com, Higgins is a 3-star analyst with an average return of -11.4% and a 43.8% success rate. |
Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial DataWednesday, Clearside Biomedical Inc (NASDAQ: CLSD) announced positive results from its OASIS Phase 1/2a trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD) patients. HC Wainwright views the 6-month results as very encouraging, considering that the enrolled patients have active subfoveal choroidal neovascularization (CNV) secondary to AMD with fluid. Hence the analyst has increased the probability of approval for CLS-AX to 25% from 20%, with |
CLSD Price Returns
| 1-mo | -11.11% |
| 3-mo | -11.76% |
| 6-mo | -7.69% |
| 1-year | -63.41% |
| 3-year | -30.23% |
| 5-year | -82.86% |
| YTD | -56.36% |
| 2021 | 0.36% |
| 2020 | -5.52% |
| 2019 | 171.03% |
| 2018 | -84.71% |
| 2017 | -21.70% |
Continue Researching CLSD
Want to do more research on Clearside Biomedical Inc's stock and its price? Try the links below:Clearside Biomedical Inc (CLSD) Stock Price | Nasdaq
Clearside Biomedical Inc (CLSD) Stock Quote, History and News - Yahoo Finance
Clearside Biomedical Inc (CLSD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...